Print This Article

Boehringer Ingelheim Vetmedica researchers reviewed and conducted an overall analysis of nine previous large-scale evaluations from five countries on three continents, comparing a single-dose Ingelvac M. hyo vaccine to conventional two-dose Mycoplasma bacterins. Data for a total of 422 groups and over 163,000 pigs were available. Only data sets from studies with sound statistical design, which defined experimental units, matched controls, and ensured other experimental quality controls were in place, were included. Those criteria ensured the results would reflect a high confidence level of repeatability in the field.

All field studies incorporated vaccination of two doses of conventional bacterin, administered to nursery-aged pigs. In all cases, Ingelvac M. hyo vaccine was administered at the same time as the first dose of conventional vaccine. Production parameters for entire barns of pigs were maintained for all field studies, and with the exception of two studies, entire barns constituted the experimental unit.

Results and discussion

Analysis of the field studies revealed a significant increase in average daily gain of pigs vaccinated with Ingelvac M. hyo as compared to those vaccinated with two-dose bacterins (p=0.018). Average growth rate for barns of pigs vaccinated with Ingelvac M. hyo was an additional 0.05 pounds per day. No significant difference was noted in feed efficiency (2.926 vs. 2.921, p=0.90) or culls and mortalities (3.6 vs. 3.5 percent, p=0.46). These data demonstrate Ingelvac M. hyo offers producers the savings in labor and reduced vaccination stress of a single dose, even while causing no reduction in efficiency or deathloss while it improves average daily gain.

Kolb, J.; Genzow, M.; Lising, R. Summary of field trials comparing Ingelvac M. hyo vs. conventional M. hyo vaccines. Proc IPVS 2004: Submitted for publication.

Rapid Onset

Flexible administration

Ingelvac M. hyo stimulates a rapid immune response that begins to protect as early as two weeks* after vaccination, and it significantly reduces the percent of lung damage following challenge at both 90 and 120 days post vaccination. That rapid onset of immunity combined with extended duration of protection increases the flexibility in administration, permitting it to be given, for instance, in early infections or at normally scheduled animal movement.

Roof M.; Kolb J. Rapid onset of protection against Mycoplasma hyopneumoniae. Proc. IPVS 2004: Submitted for publication.

Miller S.K.; et. al. Evaluation of the duration of immunity of a single dose of Ingelvac M. hyo at 90 and 120 days post vaccination. Proc IPVS 2000:500.

Rapid onset

Limited lung damage in pigs vaccinated at 3 weeks old and then challenged with a virulent M. hyopneumoniae strain two, three and four weeks later show Ingelvac M. hyo confers protection as quickly as two weeks* after vaccination.

*Data indicates onset of immunity in two weeks, Study No. 6127-0540-01P-064.

Percent of lung damage

	Challenged at 2 weeks	Challenged at 3 weeks	Challenged at 4 weeks
Challenged/not vaccinated	9.20	9.89	4.38
Challenged/vaccinated	3.93	0.79	0.88
Not challenged/not vaccinated	0.10	0.20	0.20
Similar colors are not significantly different at P<0.05.

To BIVI

Contact Information

Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt
Highway, St. Joseph,
MO 64506-2002

Phone numbers

Order Entry: 1-800-325-9167
Fax Line: 1-816-236-2717

www.bi-vetmedica.com

Enterisol and Ingelvac are registered trademarks of Boehringer Ingelheim Vetmedica, GmbH, Ingelheim, Germany.